Image Sourced ShutterStock
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Alcidion has extended its contract to 5-years with Western Sussex Hospitals for Patientrack software worth $970,000.
  • Patientrack is a software that can be used on tablets and smartphones, that helps hospitals improve patient safety, quality of care and clinical staff efficiency.
  • The 5 year deal will end in 2024

Alcidion has extended its contract to 5-years with Western Sussex Hospitals for Patientrack software worth $970,000.

Patientrack is a software which can be used on tablets and smartphones allowing hospitals to improve patient safety, quality of care and clinical staff efficiency.

The software has the capability to notices vital signs from a patients bedside to then alert hospital staff through a device.

Western Sussex Hospitals in the United Kingdom first used the technology in 2012, making it one of the longest serving users of Patientrack. The 5 year deal will end in 2024.

Alcidion purpose is to make healthcare better with smart solutions that meet the needs of hospital and healthcare worldwide.

Alcidion Managing Director, Kate Quirke is happy with the deal.

“We are delighted to continue our close partnership with Western Sussex Hospitals NHS Trust – one of our foundation customers in the UK – for the continued use of Patientrack for another five years,” she said.

ALC by the numbers
More From The Market Herald

" Anatara Lifesciences (ASX:ANR) expands eligibility criteria for IBS and psychological functioning trials

Anatara Lifesciences (ASX:ANR) has received ethics approval to expand eligibility criteria for its Irritable Bowel Syndrome…

" Althea (ASX:AGH) enters Irish medicinal cannabis market

Althea (ASX:AGH) has received approval from the Health Products Regulatory Authority (HPRA) for its CBD12:THC10 product…

" Apiam Animal Health (ASX:AHX) executes growth strategy with two acquisitions

Apiam Animal Health (ASX:AHX) has announced new acquisitions as part of its growth strategy to double…

" Next Science (ASX:NXS) appoints Oraderm Pharmaceuticals as BlastX distributor

Next Science (ASX:NXS) has signed a multi-year distribution agreement for the sale and distribution of its…